- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Cantor Fitzgerald reiterates Overweight on LeonaBio stock | 1 | Investing.com | ||
| LEONABIO Aktie jetzt für 0€ handeln | |||||
| 06.04. | Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook | 3 | Investing.com | ||
| 01.04. | LeonaBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.03. | LeonaBio GAAP EPS of -$24.70 | 12 | Seeking Alpha | ||
| 27.03. | Athira Pharma GAAP EPS of -$24.70 | 2 | Seeking Alpha | ||
| 26.03. | LeonaBio, Inc.: LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update | 268 | GlobeNewswire (Europe) | Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer... ► Artikel lesen | |
| 19.03. | LeonaBio: Aktionäre genehmigen neuen Eigenkapital-Plan und Aufstockung des genehmigten Kapitals | 2 | Investing.com Deutsch | ||
| 19.03. | LeonaBio, Inc. - 8-K, Current Report | 10 | SEC Filings | ||
| 18.03. | LeonaBio-Aktie: +167% nach NBC-Tipp | 413 | sharedeals.de | Die deutschsprachige Biotech-Szene rund um den No Brainer Club und Chefanalyst Maximilian Ruth hat erneut geliefert. Während die breite Masse erst jetzt auf die Aktie von LeonaBio aufmerksam wird, waren... ► Artikel lesen | |
| 18.02. | Mizuho upgrades LeonaBio stock rating on breast cancer drug potential | 14 | Investing.com | ||
| 18.02. | Mizuho stuft LeonaBio hoch: Aktie mit über 110 % Kurspotenzial dank Brustkrebs-Medikament | 6 | Investing.com Deutsch | ||
| 03.02. | LeonaBio, Inc.: LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer | 260 | GlobeNewswire (Europe) | BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high... ► Artikel lesen | |
| 09.01. | LeonaBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.01. | Athira Pharma roars into the new year with rebrand to LeonaBio | 4 | FiercePharma | ||
| 09.01. | Athira Pharma changes name, ticker symbol | 5 | Seeking Alpha | ||
| 09.01. | Strategische Neuausrichtung: Athira Pharma firmiert in LeonaBio um und setzt auf Krebstherapie | 6 | Investing.com Deutsch | ||
| 09.01. | Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy | 2 | Investing.com | ||
| 09.01. | Athira Pharma, Inc.: Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" | 381 | GlobeNewswire (Europe) | BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,570 | +0,54 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MAINZ BIOMED | 0,504 | 0,00 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INFLARX | 1,005 | -1,57 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 103,00 | -0,29 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| GALAPAGOS NV | 24,460 | -0,41 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,030 | -0,33 % | Cellectar Biosciences, Inc.: Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) | FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,450 | +0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| CYTOKINETICS | 54,86 | -1,01 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,193 | +8,60 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,585 | +1,60 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,450 | -1,32 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 29,220 | +0,03 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,178 | -2,85 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| BIOAGE LABS | 14,700 | +2,15 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen |
LEONABIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,340 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEONABIO INC finden Sie auf Wallstreet Online.